Sight Sciences, Inc.
$4.36
▼
-3.83%
2026-04-21 09:23:00
www.sightsciences.com
NMS: SGHT
Explore Sight Sciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$220.88 M
Current Price
$4.36
52W High / Low
$9.24 / $2.4
Stock P/E
—
Book Value
$1.2
Dividend Yield
—
ROCE
-35.58%
ROE
-50.74%
Face Value
—
EPS
$-0.74
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
186
Beta
2.49
Debt / Equity
63.77
Current Ratio
10.22
Quick Ratio
9.52
Forward P/E
-6.2
Price / Sales
2.41
Enterprise Value
$135.13 M
EV / EBITDA
-4
EV / Revenue
1.75
Rating
Buy
Target Price
$8.34
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Orthofix Medical Inc. | $12.65 | — | $507.83 M | — | -12.14% | -19.34% | $16.99 / $10.24 | $11.3 |
| 2. | Beta Bionics, Inc. | $12.91 | — | $576.08 M | — | -24.07% | -40.26% | $32.71 / $8.8 | $6.48 |
| 3. | Cytek Biosciences, Inc. | $4.57 | — | $592.62 M | — | -10.52% | -18.05% | $6.18 / $2.37 | $2.66 |
| 4. | Delcath Systems, Inc. | $10.88 | 139.76 | $377.34 M | — | 0.59% | 3% | $18.23 / $8.12 | $3.21 |
| 5. | DexCom, Inc. | $63.4 | 30.77 | $24.57 B | — | 21.72% | 34.5% | $89.98 / $54.11 | $7.14 |
| 6. | Cytosorbents Corporation | $0.65 | — | $41.24 M | — | -41.3% | -96.39% | $1.39 / $0.5 | $0.09 |
| 7. | Quanterix Corporation | $3.3 | — | $164.29 M | — | -31.92% | -34.25% | $8.77 / $3.23 | $6.33 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 20.39 M | 19.91 M | 19.56 M | 17.51 M | 19.07 M |
| Operating Profit | -3.67 M | -7.91 M | -11.67 M | -13.86 M | -11.93 M |
| Net Profit | -4.16 M | -8.17 M | -11.94 M | -14.15 M | -11.85 M |
| EPS in Rs | -0.08 | -0.15 | -0.22 | -0.26 | -0.22 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 77.36 M | 79.87 M | 81.06 M | 71.33 M |
| Operating Profit | -37.1 M | -50.53 M | -57.27 M | -83.95 M |
| Net Profit | -38.43 M | -51.51 M | -55.55 M | -86.24 M |
| EPS in Rs | -0.71 | -0.95 | -1.03 | -1.6 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 115.3 M | 142.84 M | 166.65 M | 213.07 M |
| Total Liabilities | 51.36 M | 55.32 M | 46.44 M | 53 M |
| Equity | 63.94 M | 87.52 M | 120.22 M | 160.08 M |
| Current Assets | 112.73 M | 139.77 M | 162.87 M | 209.68 M |
| Current Liabilities | 11.03 M | 15.47 M | 12.25 M | 17.82 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -29.69 M | -22.35 M | -47.18 M | -75.97 M |
| Investing CF | -0.22 M | -0.39 M | -0.79 M | -0.97 M |
| Financing CF | 1.79 M | 4.96 M | 1.1 M | 1.25 M |
| Free CF | -29.92 M | -22.74 M | -47.98 M | -76.94 M |
| Capex | -0.22 M | -0.39 M | -0.79 M | -0.97 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -1.47% | 13.63% | — | — |
| Earnings Growth % | 7.27% | 35.59% | — | — |
| Profit Margin % | -64.49% | -68.53% | -120.9% | — |
| Operating Margin % | -63.27% | -70.66% | -117.7% | — |
| Gross Margin % | 85.5% | 85.34% | 82.67% | — |
| EBITDA Margin % | -57.47% | -60.96% | -113.58% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.